http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-593121-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C215-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
filingDate 2006-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b2e6374bc3b137c7b862c1a1c178d6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16dd7006599f8da0b468d34aa2c883a5
publicationDate 2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-593121-A
titleOfInvention Liquid formulations comprising an S1P receptor modulator or agonist and propylene glycol
abstract Disclosed herein is a pharmaceutical concentrate for dilution comprising a S1P receptor modulator or agonist, propylene glycol and glycerin, wherein the S1P receptor modulator or agonist is selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2- chlorophenyl]ethyl-1,3-propane-diol, or a corresponding phosphate thereof, and 1-{ 4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl} -azetidine-3-carboxylic acid, and a pharmaceutically acceptable salt thereof. Reference has been directed, in pursuance of section 16(1) of the Patents Act 1953, to patent No. 565696.
priorityDate 2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550719
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431930790
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121468493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID72959169
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419909472
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10442
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416290180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1061

Total number of triples: 44.